Arthneeti
Vimta Labs LtdQ3 FY23

Vimta Labs Ltd Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹616P/E: 34.8Market Cap: ₹2.8K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Vimta Labs is optimistic about maintaining a good growth rate into FY 2024 and beyond, targeting 15%-18% medium-term growth.
  • The company aims to achieve INR 500 crores revenue between 2025 and 2026, retaining flexibility on timing.
  • Capacity expansion projects underway will address past constraints and support growth for at least the next 5 years.
  • Growth drivers include the food segment, which has seen steady year-on-year growth and aims to reach INR 100 crores revenue by FY 2024-25.
  • Pharma division order books remain strong with no negative impact from global slowdowns; growth driven by shift to large molecule projects.
  • Electronics testing division is in early stages but showing encouraging industry response and plans for scaling.
  • Despite strong competition, diagnostic business efforts continue with new collaborations expected to mature in coming quarters.
  • Seasonal and project shifts affect quarter-to-quarter revenue but Q4 is expected to show improvement in top and bottom lines.

See what Vimta Labs Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

- No finalized plans for new fundraising through equity or debt as of the date of this call. - The company is currently in the process of planning for capex but has not finalized the next year's capex plans (to be updated around May). - The CFO mentioned about current outstanding loans (~INR 25 crores, mostly secured). - There was no explicit mention of any immediate rights issue or equity raising planned. - The company retains flexibility to scale its investments capex-wise depending on demand, particularly in electronics and EV components testing. - The management prefers to maintain historical cost accounting for fixed assets without immediate revaluation plans. In summary, Vimta Labs Limited currently is not pursuing any new debt or equity fundraising but is assessing capex and growth needs for the near future.

See what Vimta Labs Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Vimta Labs has ongoing capex combining replacement and capacity additions (Page 14).
  • Approximately INR 27 crores capex incurred for 9 months ended December 2022; INR 22.5 crores invested in lab equipment (Page 14).
  • New facility expansion planned to be ready by early 2024, addressing capacity needs in preclinical, pharma analytical, and food services (Page 14).
  • Expansion expected to support growth for at least the next 5 years (Page 14).
  • Minor continuous capex planned for electronics testing division, adding capabilities like new chambers dependent on demand, not major large-scale capex in FY24 (Page 12, 13).
  • Future capex plans for FY24 not yet finalized; update expected in May (Page 14).
  • Capacity remodeling ongoing to optimize existing space and reduce capacity constraints (Page 14).

Track Vimta Labs Ltd — get its next earnings analysis in your feed

Margin guidance

Category 3
Future Growth Expectations for Vimta Labs Limited based on the January 30, 2023 call: - The company targets to achieve INR 500 crores revenue by 2025-2026, retaining flexibility on the exact fiscal year. - Growth rate of 15-18% medium-term is targeted and management is optimistic about maintaining this. - New capacity additions expected by end of 2023 will address current capacity constraints enabling future growth. - Q4 FY24 anticipated to see a step-up in both top line and bottom line, with EBITDA margins expected to recover from a Q3 aberration. - Diagnostics segment growth faces competition but other verticals like pharma, food, environment, and electronics testing expected to continue strong growth. - Continued investment in analytical technologies and expansion in electronics testing and pharma services will support earnings growth. - Management expects to retain or improve current EBITDA margins with growing top line. - Capital expenditure plans for FY24 under review; no major equity raise planned immediately for capex. Overall, steady revenue and earnings growth with margin improvement anticipated in coming years.

Order book

Yes
  • Vimta Labs reported a strong and robust order book as of Q3 FY23, with no negative impact seen due to recession or global slowdown (Page 8).
  • The order book growth in the pharma division has historically been 20% plus and remains strong currently (Page 8).
  • There is confidence in maintaining good growth rates into FY24 supported by a strong order book and pipeline (Page 5).
  • Some project revenues (~INR 2-3 crores) slipped from Q3 to Q4 but this is seen as a small aberration (Page 6).
  • Overall, the company expects medium-term growth of about 15-18%, driven by expanding capacities and exports (Page 5).
  • The management sees no immediate revision in their target to reach INR 500 crores revenue between FY25–FY26, supported by current order book strength (Page 5).

How does Vimta Labs Ltd rank vs peers in Healthcare Services?

Pro feature
ThisVimta Labs Ltd
Rev 3Mar 3
See where Vimta Labs Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Vimta Labs Ltd rank in Healthcare Services?

Compare Vimta Labs Ltd against every Healthcare Services company (Q3 FY23) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Continue your research

What Vimta Labs Ltd's management said in earlier quarters

Others in Healthcare Services this season

  • Metropolis Healt (Q1 FY27)

    East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…

  • Apollo Hospitals (Q1 FY27)

    IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…

  • Health X Platform Ltd (Q1 FY27)

    July monthly revenue stood at INR 150+ crores, indicating strong growth momentum. Key concall takeaways from Health X Platform Ltd's Q1 FY27 earnings call…

  • Shalby Ltd (Q1 FY27)

    Shalby MedTech showed strong revenue growth: ₹47 crores in Q1 FY27, a 53% YoY increase. Key concall takeaways from Shalby Ltd's Q1 FY27 earnings call — and how…

Compare:vs Apollo Hospitalsvs Max Healthcare Institute Ltdvs Fortis Health.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →